hrp0095rfc4.6 | Fat, Metabolism and Obesity | ESPE2022

European Consortium of Lipodystrophies Registry, 2022

von Schnurbein Julia , Gambinieri Alessandra , Fernández-Pombo Antia , Akinci Baris , Vatier Camille , Cecchetti Carolina , Adiyaman Cem , Vigoroux Corrine , Araujo-Vilar David , Savage David , Gilio Donatella , Bismuth Elise , Sorkina Ekaterina , Vorona Elena , Santos Silva Ermelinda , Nobecourt Estelle , Csajbok Eva , Santini Ferrucio , Prodam Flavia , Nagel Gabriele , Aimaretti Gianluca , Latanzi Giovanna , Ceccarini Giovanni , Novelli Giuseppe , Yildirim Simsir Ilgin , Jeru Isabelle , Štotl Iztok , Carel Jean-Claude , Writzl Karin , Heldt Katrin , Miehle Konstanze , Kleinendorst Lotte , D’Apice Maria-Rosaria , Beghini Mariana , Vantyghem Marie-Christine , Broekema Marjoleine , Faßhauer Mathias , Stumvoll Michael , Sbraccia Paolo , Ozen Samim , Magno Silvia , Scherer Thomas , Daffara Thomaso , Pekkolay Zafer , Wabitsch Martin

Background: Lipodystrophy syndromes comprise a large group of extremely rare diseases characterized by loss or dysfunction of adipose tissue. Due to their extreme rarity and variability, research in the field of lipodystrophy is difficult for single centres warranting larger co-operations.Methods: Therefore, the European Consortium of Lipodystrophies decided to found an international registry in 2016. This registry is ba...

hrp0095p1-483 | Fat, Metabolism and Obesity | ESPE2022

The ecology of the microbiome in children with congenital generalized lipodystrophy type 4 (CGL4) is quickly modified after metreleptin treatment

Mancioppi Valentina , Daffara Tommaso , Caputo Marina , Bellone Simonetta , Massa Nadia , Caramaschi Alice , Mignone Flavio , Romanisio Martina , Rabbone Ivana , Giordano Mara , Aimaretti Gianluca , Bona Elisa , Prodam Flavia

Introduction: Lipodystrophy syndromes are characterized by a progressive metabolic impairment secondary to adipose tissue dysfunction and genetic background. The role of microbiota is still uninvestigated.Objective: Evaluate the gut microbiome ecology in relation to dietary and clinical parameters in two infant siblings with congenital generalized lipodystrophy type 4 (CGL4) before and after treatment with recombinant le...

hrp0084p3-1240 | Turner | ESPE2015

Patients with Turner’s Syndrome Should Have Ophthalmological Examination before Commencing Recombinant GH Treatment

Alsaffar Hussain , Thomason Eleanor , Blair Joanne , Didi Mohammed

Introduction: Turner’s syndrome (TS) is caused by an abnormality of one of the X chromosomes. Short stature or slow growth is one of the first manifestations of TS and it is recommended that GH therapy should be initiated as soon as it becomes apparent that affected girls are not growing normally to optimise final adult height. Idiopathic intracranial hypertension (IIH) is a well-known side effect of GH therapy, and it has also been reported in girls with TS with or witho...

hrp0084p1-138 | Turner & Puberty | ESPE2015

Weight Gain in Turner Syndrome: Association to Puberty Induction?

Reinehr Thomas , Lindberg Anders , Toschke Christina , Cara Jose , Chrysis Dionisios , Camacho-Hubner Cecila

Background: We have recently reported a BMI-SDS increase in girls with Turner syndrome (TS) treated with growth hormone (GH) (1).Objective and hypothesis: We hypothesise that puberty induction in TS is associated with weight gain.Method: We analysed the weight changes (BMI-SDS) of 888 girls with TS in the Pfizer International Growth Database (KIGS). Overweight was defined by a BMI >90th percentile and obesity by a BMI >97th...

hrp0086s1.1 | Innovative therapies in bone and mineral metabolism | ESPE2016

Innovative Therapies in Bone and Mineral Metabolism: Anti FGF23 in X-linked Hypophosphatemia

Carpenter Thomas

Background: Hypophosphatemia due to excess urinary phosphate losses and rachitic bone disease occur in several related disorders. The most common form of the heritable hypophosphatemic disorders, X-linked hypophosphatemia (XLH), is due to loss-of-function mutations of the osteocyte/osteoblast protein, PHEX. Reduced abundance of phosphate transporters on the luminal surface of renal tubular cells in the syngeneic animal model of XLH, and inappropriately normal (or frankly low) ...

hrp0086s3.2 | Optimizing nocturnal diabetes control | ESPE2016

Optimising Nocturnal Glucose Control in Children with T1D: Therapeutic Implications

Danne Thomas

Background: Nocturnal hypoglycemia is not regularly predictable on the basis of a bedtime BG level and can only be confirmed by BG tests at regular intervals during the night or continuous glucose monitoring (CGM).Objective and hypotheses: A bedtime snack containing carbohydrate as well as fat and protein may be useful in preventing nocturnal hypoglycemia, but this should not be at the expense of high overnight BG levels. In many individuals, a lowering ...

hrp0086wg4.5 | ESPE Bone and Growth Plate Working Group (BGP) | ESPE2016

FGF23, Klotho and PTH in the Regulation of Mineral Homeostasis

Carpenter Thomas

Background: The Fibroblast Growth Factors (FGFs) are a large family of proteins including paracrine, intracrine, and endocrine FGFs. Paracrine and endocrine FGFs interact with specific cell surface receptors (FGFRs) that, via intracellular tyrosine kinase activity, initiate a cascade of downstream intracellular events. Specificity of paracrine/autocrine FGF activity is provided locally by the local production of these FGFs and their cognate receptors. In contrast, endocrine FG...

hrp0086wg5.2 | ESPE Diabetes Technology and Therapeutics Working Group | ESPE2016

SWEET: Developing Centers of Excellence (CoR)

Danne Thomas

Background: SWEET (www.sweet-project.eu) is a non-profit entity endorsed by ISPAD aiming to create an extensive network of certified CoRs for childhood diabetes in order to ensure high quality care.Objective and hypotheses: SWEET aims at an improved and more uniform care for people with diabetes through comparing processes and outcomes among participating members. The results of data analysis are conveyed to memb...

hrp0082wg4.2 | Obesity | ESPE2014

Natural Course of Impaired Glucose Tolerance in Obese Children

Reinehr Thomas

Obesity in childhood is associated to several cardiovascular risk factors summarized in the definition of metabolic syndrome such as hypertension, dyslipidemia and impaired glucose tolerance. Besides others, the pathogenetic background is insulin resistance, which deteriorates in mid puberty and normalizes at end of puberty. Accordingly, blood pressure, lipids, fasting glucose and 2 h glucose in oGTT increased from prepubertal stage to pubertal stage and decreased from puberta...

hrp0084wg2.6 | Diabetes Technology and Therapeutics Thursday, 1 October | ESPE2015

Type 2 Diabetes Mellitus in Adolescence

Reinehr Thomas

Type 2 diabetes mellitus (T2DM) is emerging as a new clinical problem within pediatric practice. Recent reports indicate an increasing prevalence of T2DM in children and adolescents around the world in all ethnicities, even if the prevalence of obesity is not increasing any more. There are great differences in T2DM prevalence worldwide. The majority of young people diagnosed with T2DM was found in specific ethnic subgroups such as African-American, Hispanic, Asian/Pacific Isla...